Meeting Information

General information about the meeting can be found below and will be updated with any additional details as they become available.

Learner Notification
XXXIII International Symposium on Technical Innovations in Laboratory Hematology 2020
June 22 - September 25, 2020
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support 
No in-kind commercial support was received for this educational activity.
Satisfactory Completion  
Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.  
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Society for Laboratory Hematology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 34.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  
Objectives - After Attending This Program You Should Be Able To:
  1. Define new technological developments in laboratory hematology testing
  2. Implement technological advances in the routine hematology laboratory
  3. Describe the latest diagnostics capabilities and directions in cellular analysis and flow cytometry
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
First Name
Last Name
Commercial Interest
Novartis;Research/Grant, Advisory Board
Sysmex; Consultant
Storm Therapeutics Ltd, Cancer Therapeutics CRC, Cambridge Epigenetix, GSK; Advisory board
Haematex Research
Eli Lilly and Co.,  Abbvie, Cellerant Therapeutics; Research/Grants, Seattle Genetics; Consultant, Miltenyi; Advisory board
How to Get Your Certificate:
ISLH will send an email to all meeting registrants after the conclusion of the virtual meeting with instructions for claiming educational credits.

The conference proceedings are available online at 

PLAY the ISLH Virtual Bingo Game! Simple "scan" your badge at both the Virtual Corporate Workshops and Virtual Exhibit Booths for a chance to win a 250 USD amazon gift card.

Latest News